Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
Date:5/26/2012

oking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unfo
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
2. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
3. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
4. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
5. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
6. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
7. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
8. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
9. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... Research and Markets  has announced the ... by Application, Geography - Global Analysis and Forecast (2014 ... Organic electronics, also called as polymer electronics or ... deals with small conductive molecules and electrically conductive polymers. ... polymers are carbon based, made using synthetic strategies developed ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... ChemAxon, a software,solutions provider for cheminformatics, today announced ... for working with chemical and,other data on local ... and form building, relational data support, advanced query ... the vast,majority of functionality and is free for ...
... CITY, Calif., Aug. 21 Codexis, Inc., a private,biotechnology ... the new position of Vice President and Managing Director ... first,facility in Asia. Dr. Daussmann will report to Alan ... to name Dr. Daussmann to this important new,position on ...
... to Increase Efficiency, MINNEAPOLIS, Aug. 21 ... a leading provider of enterprise-wide advanced,visualization and ... its,next generation enterprise-wide advanced visualization and analysis ... and ViTALConnect(R) 4.1. This,comprehensive package offers powerful ...
Cached Biology Technology:Instant JChem 2.0 Released: Instant JChem Personal Free for All Users 2Codexis Appoints Singapore Laboratories Managing Director 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... market releases photos and video of the recent opening bell at ... . Gino Pereira , CEO of NXT-ID ... Chad A. Verdi rang the bell.  ... employees "for their work and dedication in bringing the world,s next ...
(Date:10/14/2014)... years since T. rex took its last ... is breathing life back into dinosaurs using high-powered computer ... has important implications for how dinosaurs used their noses ... of smell and cool their brains. , "Dinosaurs ... Jason Bourke, lead author of the new study published ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... Biometric Time Clock Security and ... ATLANTA, Nov. 27 M2SYS Technology, ... that Software,Techniques Inc. has enhanced their TimeKRON ... Bio-SnapON(TM) solution., Bio-SnapON(TM) allows companies to ...
... for High-Performance Notebook Computers ... and Consumer Electronic Applications, SUNNYVALE, ... a leading supplier of innovative computer products including,hard disk ... of its MHZ2 BH series mobile hard disk drive ...
... has both UCLA and a team of enterprising UCLA scientists ... In 1996, a unique collaboration of leading ... company Agensys Inc. and the company now stands to ... making it one of the largest Los Angeles-based private biotech ...
Cached Biology News:Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time & Attendance Solutions 2Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 2Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 3Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Mouse anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... assay dependent dilution. ICC: Use at an assay ... 5 - 10 ug/ml, this concentration is determined ... molecular weight: 40 kDa. Not tested in other ...
SHP-2 Antibody...
... Glycine Transporter 2, Neuronal (GLYT2). The ... from the central nervous system. The staining ... pattern described using in situ hybridization with ... has been described for glycinergic neurons. Preabsorption ...
Biology Products: